Rubicon Research profit rises 32% but falls sequentially

Rubicon Research Limited reported standalone net profit of Rs 60.62 crore for the quarter ended September 30, 2026, 32.3% above Rs 45.812 crore a year earlier, although revenue from operations fell 10.3% sequentially to Rs 383.572 crore from Rs 427.730 crore in the June 2026 quarter.

How did Rubicon Research perform in September 2026?

Rubicon Research recorded year-on-year growth in standalone revenue and profit during the September 2026 quarter, while both measures declined from the preceding June quarter. Revenue from operations was Rs 383.572 crore, compared with Rs 336.467 crore in the quarter ended September 30, 2025, and Rs 427.730 crore in the quarter ended June 30, 2026. Total income, including Rs 2.262 crore of other income, reached Rs 385.834 crore.

Profit before tax was Rs 81.563 crore, up from Rs 61.630 crore a year earlier but below Rs 110.657 crore in June 2026. Net profit after tax was Rs 60.62 crore, against Rs 45.812 crore in September 2025 and Rs 82.449 crore in the prior quarter. Basic earnings per share were Rs 3.66, compared with Rs 2.97 a year earlier and Rs 4.99 sequentially.

The Board approved the unaudited standalone results on November 5, 2026, after review by the Audit Committee. Deloitte Haskins & Sells LLP conducted a limited review and stated that nothing had come to its attention to indicate that the standalone statement was materially misstated under the applicable reporting requirements.

What changed in Rubicon Research's costs and profit?

Rubicon Research's September-quarter expenses increased from a year earlier but fell from the June quarter, matching the direction of income. Total expenses were Rs 304.271 crore, versus Rs 276.349 crore in September 2025 and Rs 319.484 crore in June 2026. The Rs 47.855 crore year-on-year rise in total income exceeded the Rs 27.922 crore increase in expenses, lifting profit before tax by Rs 19.933 crore.

Cost of materials consumed rose to Rs 132.226 crore from Rs 114.427 crore a year earlier and Rs 125.447 crore in June 2026. Employee benefits expense increased to Rs 54.945 crore from Rs 40.752 crore and Rs 51.521 crore, respectively. Other expenses were Rs 113.477 crore, above Rs 99.152 crore in the prior-year quarter but below Rs 115.923 crore in the preceding quarter.

Changes in inventories of finished goods and work-in-progress reduced reported expenses by Rs 13.453 crore in the September quarter. This contrasts with an expense of Rs 3.035 crore in September 2025 and an expense of Rs 10.012 crore in June 2026. Finance costs declined year on year to Rs 6.464 crore from Rs 9.207 crore, but increased from Rs 6.013 crore in the June quarter; depreciation and amortisation rose to Rs 10.612 crore from Rs 9.776 crore a year earlier.

Tax expense was Rs 20.943 crore, compared with Rs 15.818 crore in September 2025 and Rs 28.208 crore in June 2026. Other comprehensive loss was Rs 1.493 crore, after other comprehensive income of Rs 0.052 crore in the prior quarter. Total comprehensive income consequently stood at Rs 59.127 crore, compared with Rs 45.449 crore a year earlier and Rs 82.501 crore sequentially.

What do Rubicon Research's first-half cash flows show?

Rubicon Research reported higher first-half profit but lower net operating cash flow for the half year ended September 30, 2026. Net cash generated from operating activities was Rs 43.577 crore, down from Rs 56.297 crore in the corresponding prior-year period, despite profit before tax increasing to Rs 192.220 crore from Rs 109.066 crore. Cash generated from operating activities before income tax was Rs 86.235 crore, versus Rs 66.417 crore a year earlier.

Working-capital movements absorbed cash in the six months. Inventories increased by Rs 41.973 crore and trade receivables increased by Rs 63.914 crore, compared with increases of Rs 52.339 crore and Rs 36.081 crore, respectively, in the prior-year period. Trade payables declined by Rs 17.178 crore, while net income tax paid rose to Rs 42.658 crore from Rs 10.120 crore.

For the half year, revenue from operations rose 32.0% to Rs 811.302 crore from Rs 614.493 crore, while net profit after tax increased to Rs 143.069 crore from Rs 80.964 crore. Finance costs declined to Rs 12.477 crore from Rs 18.055 crore, whereas employee benefits expense rose to Rs 106.466 crore from Rs 77.882 crore. Rubicon Research identified sale of pharmaceutical products as its single reportable business segment under Indian Accounting Standard 108.

Investing activities used Rs 133.284 crore in the half year, compared with an outflow of Rs 113.039 crore a year earlier. The 2026 investing cash flow included Rs 175.917 crore paid for the acquisition of a subsidiary through a business combination and Rs 49.121 crore of capital expenditure on property, plant and equipment and intangible assets. Financing activities generated Rs 96.071 crore, including Rs 90.613 crore of net proceeds from current borrowings.

How did Rubicon Research's balance sheet and plans change?

Rubicon Research's standalone total assets rose to Rs 2,209.953 crore at September 30, 2026, from Rs 1,975.503 crore at March 31, 2026. Investments in subsidiaries increased to Rs 214.133 crore from Rs 35.658 crore, while trade receivables rose to Rs 767.191 crore from Rs 713.434 crore and inventories increased to Rs 389.793 crore from Rs 347.820 crore. Cash and cash equivalents were Rs 98.585 crore, against Rs 91.779 crore at the financial year-end.

Total borrowings, comprising current and non-current borrowings, were Rs 398.370 crore at September 30, 2026, compared with Rs 259.369 crore at March 31, 2026. Current borrowings increased to Rs 209.895 crore from Rs 116.346 crore, while non-current borrowings rose to Rs 188.475 crore from Rs 143.023 crore. Equity, consisting of share capital and other equity, increased to Rs 1,484.530 crore from Rs 1,353.273 crore.

The Board approved the proposed amalgamation of KisHealth Tech Private Limited with Rubicon Research on July 20, 2026. The scheme was filed with the Registrar of Companies, Navi Mumbai on August 3, 2026, under the fast-track merger route, but had not become effective by September 30, 2026; no accounting effect was therefore recorded in the reported results.

Rubicon Research had received net initial public offering proceeds of Rs 471.274 crore in the year ended March 31, 2026, after estimated issue expenses of Rs 28.726 crore. Of this amount, Rs 406.679 crore had been utilised by September 30, 2026, leaving Rs 64.595 crore unutilised. The Board extended the deadline for using the balance to March 31, 2027.

Conclusion

The standalone results show that year-on-year earnings expansion continued in the September quarter, as Rs 47.855 crore of additional total income exceeded the Rs 27.922 crore rise in expenses. However, profit after tax was Rs 21.829 crore lower than in June 2026, and the first-half conversion of profit into operating cash was affected by Rs 105.887 crore of combined increases in inventories and trade receivables.

The next disclosed milestones are the use of Rs 64.595 crore of remaining initial public offering proceeds by March 31, 2027 and the completion of approvals and compliance for the KisHealth Tech Private Limited amalgamation. Of the unutilised proceeds, Rs 18.589 crore was allocated to borrowing repayment and Rs 46.006 crore to inorganic growth, strategic initiatives and general corporate purposes as of September 30, 2026.